Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Zealand Pharma A/S
22ZZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. Address: Sydmarken 11, Søborg, Denmark, 2860
Analytics
Preço Alvo de Wall Street
206.71 EURRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 22Z
Análise de Dividendos 22Z
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos 22Z
Avaliação de ações 22Z
Relatório 22Z
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |